Cargando…
Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report
Pulmonary pleomorphic carcinoma (PPC) is a rare type of non‐small cell lung cancer (NSCLC) with a more aggressive clinical course and a worse outcome than other types of NSCLC. Pembrolizumab, a monoclonal antibody targeting programmed cell death‐1 (PD‐1), has been approved as the first‐line treatmen...
Autores principales: | Kim, Tae‐Hun, Park, Sun Hyo, Hwang, Ilseon, Lee, Jin Hee, Kim, Jin Hee, Kim, Hae Won, Kim, Hyun Jung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580814/ https://www.ncbi.nlm.nih.gov/pubmed/34795901 http://dx.doi.org/10.1002/rcr2.875 |
Ejemplares similares
-
Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020) -
The Successful Treatment of Pulmonary Pleomorphic Carcinoma with Pembrolizumab: A Case Report
por: Matsumoto, Yoko, et al.
Publicado: (2017) -
Tracheal pleomorphic adenoma with coexisting pulmonary tuberculoma
por: Kim, Jehun, et al.
Publicado: (2018) -
A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab
por: Sako, Masahiro, et al.
Publicado: (2021) -
Expression of CD99 in Pleomorphic Carcinomas of the Lung
por: Yoo, Seong-Ho, et al.
Publicado: (2005)